- What Mission Street has added two life science investors to its advisory board
- Why Peter Finan and Jonathan Hepple have extensive experience in venture capital
- What next Property developer is currently pursuing a string of life science projects
Mission Street has expanded its advisory board with the appointment of life science venture capital specialists Peter Finan and Jonathan Hepple.
Finan previously served as partner at transatlantic venture capital firm Epidarex Capital. He has three decades of experience in the drug discovery business and was involved in the formation of 25 new life science companies in the UK and US. Finan was also responsible for the redesign of Novartis’ research facilities in the UK and in Cambridge, Massachusetts.
Hepple is the co-founder of life science venture capital firm Rosetta Capital. He also serves as strategic advisor to Oxford Science Enterprises and is on the board of three biotechnology firms.
Both Finan and Hepple will join Tim Funnell, a partner at venture capital firm Monograph Capital, on the board. Funnell is the CEO of gene therapy manufacturing company Ascend and was a co-founder of MiroBio, which is now a subsidiary of US-listed Gilead Sciences.
Artem Korolev, founder and CEO of Mission Street, said: “We are privileged to have a board with such outstanding expertise and track record in founding, investing in and managing companies across the R&D cycle, at a variety of scales from company creation to international pharma.”
Mission Street is joining forces with BentallGreenOak on a new 100,000 sq ft life sciences facility in the Cambridge Southern Cluster. The property developer is also seeking consent for the construction of a research & development hub at the DFS and Carpetright site on Botley Road in Oxford.
